FundraiseBase by

SonoMind

$25.8M raised across 2 rounds tracked here. Latest: Series A, $23.5M on 12 May 2026.

Total raised: $25.8M
Rounds: 2

Latest round Series ACountry FranceSector Health

Rounds 2

$23.5MSeries A, 12 May 2026

Series A co-led by Critical Path Ventures and Bpifrance to start clinical trials, targeting approval by 2029.

Amount: $23.5M
Stage: Series A
Announced: 12 May 2026
Lead: Critical Path Ventures
Other investors: Bpifrance
Use of funds: Series A co-led by Critical Path Ventures and Bpifrance to start clinical trials, targeting approval by 2029.
Checked: Amount and date checked against the press source
Source: SonoMind raises $23.5M for focused ultrasound depression therapy massdevice.com

$2.4MSeed, 24 September 2025

€2M seed from Critical Path Ventures plus €1M France 2030 non-dilutive aid fund device development toward trials.

Amount: $2.4M
Stage: Seed
Announced: 24 September 2025
Lead: Critical Path Ventures
Use of funds: €2M seed from Critical Path Ventures plus €1M France 2030 non-dilutive aid fund device development toward trials.
Checked: Announced by the company
Sources: Sonomind raises 3M euros to treat severe depression pharmiweb.com
Sonomind raises 3M euros to treat severe depression mind.eu.com

Company

Low-intensity focused ultrasound therapy for treatment-resistant depression

Based in: Paris, France
Sector: Health
Website: sonomind.com ↗

Links

Website: sonomind.com ↗

Questions

How much has SonoMind raised?

SonoMind has raised $25.8M across 2 rounds tracked by FundraiseBase. The latest is Series A of $23.5M, announced on 12 May 2026.

Who invested in SonoMind?

Critical Path Ventures led. Investors include Critical Path Ventures and Bpifrance.